Guess how many drug candidates we’ve identified? We just hit 77. Over the past 17 years, our team has delivered an unmatched number of preclinical drug candidates, many of which have progressed to clinical proof-of-concept or beyond. Combined with more than 320 patents, our results speak for themselves. Collaboration fosters innovation. Shouldn’t our next success be yours? Explore the advantages of Charles River’s integrated drug discovery program at www.criver.com/IDD.